Is Citius Oncology, Stock a Good Investment?
Citius Oncology, Investment Advice | CTOR |
- Examine Citius Oncology,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Citius Oncology,'s leadership team and their track record. Good management can help Citius Oncology, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Citius Oncology,'s business and its evolving consumer preferences.
- Compare Citius Oncology,'s performance and market position to its competitors. Analyze how Citius Oncology, is positioned in terms of product offerings, innovation, and market share.
- Check if Citius Oncology, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Citius Oncology,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Citius Oncology, stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Citius Oncology, is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Citius Oncology, Stock
Researching Citius Oncology,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if Citius Oncology, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Citius Oncology,'s research are outlined below:
| Citius Oncology, generated a negative expected return over the last 90 days | |
| Citius Oncology, has high historical volatility and very poor performance | |
| Citius Oncology, has some characteristics of a very speculative penny stock | |
| Citius Oncology, was previously known as TenX Keane Acquisition and was traded on NASDAQ Exchange under the symbol TENK. | |
| Citius Oncology, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab and LYMPHIR in Cancer Patients with Recurrent Solid Tumors |
Citius Oncology,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 116.23 M.Basic technical analysis of Citius Stock
As of the 24th of November, Citius Oncology, shows the Standard Deviation of 6.43, risk adjusted performance of (0.11), and Mean Deviation of 4.87. Citius Oncology, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Citius Oncology, market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Citius Oncology, is priced correctly, providing market reflects its regular price of 0.85 per share. Given that Citius Oncology, is a hitting penny stock territory we recommend to closely look at its jensen alpha.Citius Oncology,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Citius Oncology, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Citius Oncology,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Citius Oncology, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Holubiak Myron Z over a month ago Acquisition by Holubiak Myron Z of 500000 shares of CTOR at 2.15 subject to Rule 16b-3 | ||
Webb Carol over three months ago Insider Trading |
Understand Citius Oncology,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Citius Oncology,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 4.87 | |||
| Coefficient Of Variation | (669.04) | |||
| Standard Deviation | 6.43 | |||
| Variance | 41.36 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.23) | |||
| Total Risk Alpha | (1.98) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 27.83 | |||
| Value At Risk | (10.29) | |||
| Potential Upside | 10.08 | |||
| Skewness | 0.5322 | |||
| Kurtosis | 0.2028 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 4.87 | |||
| Coefficient Of Variation | (669.04) | |||
| Standard Deviation | 6.43 | |||
| Variance | 41.36 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.23) | |||
| Total Risk Alpha | (1.98) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 27.83 | |||
| Value At Risk | (10.29) | |||
| Potential Upside | 10.08 | |||
| Skewness | 0.5322 | |||
| Kurtosis | 0.2028 |
Consider Citius Oncology,'s intraday indicators
Citius Oncology, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Citius Oncology, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Citius Oncology, time-series forecasting models is one of many Citius Oncology,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Citius Oncology,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Citius Stock media impact
Far too much social signal, news, headlines, and media speculation about Citius Oncology, that are available to investors today. That information is available publicly through Citius media outlets and privately through word of mouth or via Citius internal channels. However, regardless of the origin, that massive amount of Citius data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Citius Oncology, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Citius Oncology, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Citius Oncology,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Citius Oncology, alpha.
Citius Oncology, Corporate Executives
Elected by the shareholders, the Citius Oncology,'s board of directors comprises two types of representatives: Citius Oncology, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Citius. The board's role is to monitor Citius Oncology,'s management team and ensure that shareholders' interests are well served. Citius Oncology,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Citius Oncology,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jaime Bartushak | CFO Treasurer | Profile |
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.